CA-TTTECH-INDUSTRIAL
25.5.2021 10:02:06 CEST | Business Wire | Press release
TTTech Industrial Automation AG has acquired core technology and strategic customers from pioneering fog/edge computing start-up Nebbiolo Technologies in a deal closed in May. Integrating features and know-how from Nebbiolo Technologies will support TTTech Industrial’s commitment to delivering the world’s most advanced industrial edge computing platform to its customers. TTTech Industrial has also founded a US subsidiary in Silicon Valley to expand its activities in the North American market. Kannan Devarajan, one of the co-founders of Nebbiolo Technologies has joined TTTech Industrial North America Inc. as Managing Director.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210525005037/en/
TTTech Industrial is a leading provider of industrial IoT solutions, and partners with key players in IoT such as Intel and Microsoft. The company’s Nerve software platform has been at the forefront of industrial edge computing since its launch in 2016. The foundation of TTTech Industrial North America supports the expansion of commercial operations in the US and Canada, with the technology and customer assets acquired from Nebbiolo Technologies forming the nucleus of these activities.
Nebbiolo Technologies is renowned as the pioneer of fog computing, with patented technology that is foundational to industrial edge computing concepts. The company was named a Gartner Cool Vendor in 2017 and was recognized as the Customer Value Leader in the IIoT edge computing market by Frost & Sullivan in 2019. The combination of existing Nerve product features with Nebbiolo Technologies’ expertise will provide customers with an unparalleled solution for software management at the edge, remote connectivity, edge analytics, high-availability, and security.
TTTech Industrial has an existing customer base of machine builders and system integrators based in Europe, the US and Asia. Aside from growing its operations in North America and Asia, this deal also allows TTTech Industrial to widen the scope of its activities to new industries such as energy, oil/gas and auto manufacturing, strengthen the global reach of its edge computing solutions and bolster go-to-market activities in Europe.
"The launch of our US subsidiary marks a significant step for our company. Our location in Silicon Valley brings us closer to customers and allows us to tap into a pool of the world's best software engineering talent. The integration of assets from Nebbiolo Technologies enables us to offer even more advanced industrial edge computing solutions to new and existing customers in a wider range of application fields,” explains Thomas Berndorfer, Member of the Executive Board, TTTech Industrial Automation AG.
“I am very proud to be leading TTTech Industrial's expansion into North America. My team and I bring a wealth of experience in edge computing solutions that will contribute to making Nerve the platform of choice for industrial automation customers. In addition, we will provide customers with expert local sales and technical support, as well as custom feature development," says Kannan Devarajan, Managing Director, TTTech Industrial North America.
CEO and co-founder of Nebbiolo Technologies Chandra Joshi states, “We have been partnering with TTTech Industrial from the outset of our journey. I am confident that the integration of Nebbiolo’s technology with TTTech Industrial’s Nerve product line will create a leading-edge computing platform to enable existing and new customers to accelerate their digital transformation.”
About TTTech Industrial Automation AG
TTTech Industrial aspires to unlock the incredible potential of industrial automation. It combines transformative technologies with hands-on experience in critical real-time systems to offer customers flexibility, reliability and choice. TTTech Industrial operates under the umbrella of the TTTech Group, a leading provider of safe networked computing platforms, with cross-industry experience from more than 20 years of operation.
TTTech Industrial product lines Nerve, Slate and Flexibilis are designed to converge and connect automation systems. Nerve is a flexible, open industrial edge computing platform that enables users to access data, manage devices and deploy applications remotely. Slate is a deterministic networking platform that provides comprehensive TSN solutions. Flexibilis is a redundant networking product portfolio that delivers high-availability seamless redundancy for a wide range of industrial applications, most notably in the energy industry.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005037/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom